Earlier, we shared the high-level results of our Q3’25 Psychedelic Investor Survey, our fourth such survey. Here, we take a closer look at investors’ qualitative responses to provide a better picture of their key areas of excitement. (We will explore key areas of concern in our third and final article detailing these survey results.)
In general, investor enthusiasm for bringing psychedelic therapies to market remains strong, but regulatory hurdles continue to be the dominant concern. Additionally, although most investors view changes in the U.S. administration positively, a growing share cites political uncertainty as a concern.
At the same time, attention is shifting toward commercial viability after approval: investors increasingly worry about rollout challenges, infrastructure and workforce gaps, and uncertain reimbursement pathways. Conversely, anxiety about trial outcomes and development timelines has abated, likely buoyed by several positive readouts since the start of 2025.
Contents
- Regulatory & Legislative Barriers
- Commercialisation & Commercial Viability
- Safety & Ethics
- Political Uncertainty
- Trial Outcomes & Development Timelines
- Return on Investment
- Stigma
- Big Pharma Interference
- Bankruptcy & Company Execution
- Funding (Sources & Uses)
- Next: What are Psychedelics Investors Concerned About?
***
Regulatory & Legislative Barriers
As mentioned, these perceived barriers and challenges continue to loom large among investors of all stripes, despite many viewing the current U.S. administration as being more amenable to psychedelic therapies.
It’s quite simple, really: investors cited potential regulatory headwinds, bureaucracy, and hurdles, predominantly in the pre-approval environment, as well as in the review of a new drug application…
To continue reading, please log in or join Pα+…
Join Pα+ Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Already a member? Log In
✓ Regular Bulletins covering key topics and trends in the psychedelics space
✓ Regular articles and deep dives across psychedelic research, policy and business
✓ Interviews with insiders
✓ Monthly interactive database and commentary on psychedelic patents
✓ Quick-take analysis of major developments
✓ A Library of primers and explainers
✓ Access to our full back catalogue
